EV Biologics Corp, announced that it has closed a $500,000 interest-free loan from a related party. This funding will provide for further development of exosome - and other nanoparticle-enriched biological products, as well as optimization of their scalable, cGMP-compatible, biomanufacturing process. The funds will be also used for comprehensive product analysis by several leading independent laboratories.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6021 USD | -3.21% | 0.00% | -39.79% |
2023 | EV Biologics, Inc. Closes A $500,000 Interest-Free Loan | CI |
2023 | Ev Biologics Completes Production of Cutting-Edge Msc Exosome-Based Therapeutic | CI |
1st Jan change | Capi. | |
---|---|---|
-39.79% | 6.36M | |
+18.72% | 48.44B | |
+8.09% | 16.74B | |
-3.19% | 15.77B | |
-9.24% | 11.23B | |
+32.47% | 9.22B | |
-4.30% | 7.83B | |
+40.74% | 7.65B | |
-5.24% | 7.57B | |
+105.28% | 7.38B |
- Stock Market
- Equities
- YECO Stock
- News EV Biologics, Inc.
- EV Biologics, Inc. Closes A $500,000 Interest-Free Loan